HIV and antiretroviral drug resistance
https://doi.org/10.22625/2072-6732-2025-17-2-32-41
Abstract
The article presents modern views on the causes of the formation of drug-resistant HIV strains. The main reasons for the ineffectiveness of antiretroviral therapy are low patient adherence to treatment, lack of combination therapy, and high rate of viral recombination, which leads to the emergence of HIV drug resistance mutations. The data on HIV drug resistance mutations and their prevalence in different populations and in different age groups were analyzed. The most common HIV drug resistance mutations M184V and K103N are found in both acquired and transmitted HIV drug resistance, these mutations cause drug resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors and are found in people living with HIV. Due to the high prevalence of drug-resistant strains, testing of people with HIV infection for HIV drug resistance mutations is necessary in cases of treatment failure and in patients in areas where the percentage of transmitted drug resistance is high.
About the Authors
N. V. Nemchinova
Scientific Centre of Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
Irkutsk
T. A. Bairova
Scientific Centre of Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
Irkutsk
A. Yu. Sambyalova
Scientific Centre of Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
Irkutsk
E. V. Belyaeva
Scientific Centre of Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
Irkutsk
O. A. Ershova
Scientific Centre of Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
Irkutsk
References
1. Global HIV & AIDS statistics – Fact sheet. UNAIDS. Available from: https://www.unaids.org/ru/resources/factsheet. [Accessed: 31st October 2024].
2. UN General Assembly, Political Declaration on HIV and AIDS: On the Fast Track to Accelerating the Fight against HIV and to Ending the AIDS Epidemic by 2030: resolution / adopted by the General Assembly, A/RES/70/266, 22 June 2016. Available from: www.unaids.org/sites/default/files/media_asset/2016-political-declaration-HIV-AIDS_ru.pdf. [Accessed: 1st February 2024].
3. Certificate of HIV in Russia dated December 31, 2023. Federal Scientific and Methodological Center for the Prevention and Control of AIDS. Available from: http://www.hivrussia.info/wp-content/uploads/2024/09/spravka-vich-v-rossii-2023-god.pdf. [Accessed: 31st October 2024].
4. Latysheva, I.B. HIV infection in children in the Russian Federation / I.B. Latysheva, E.E. Voronin // Aktualnye voprosy VICh-infektsii. Okhrana zdorovya materi i rebenka: Materialy konferentsii. SPb.: Chelovek i ego zdorovye. – 2018. – P. 9–12.
5. Sambyalova, A.Yu. Virological failure of antiretroviral therapy and associated social and clinical factors in children and adolescents living with HIV / A.Yu. Sambyalova, T.A. Bairova, T.L. Manaenkova // Journal Infectology. – 2022. – Vol. 14, No. 5. – P. 51-59. doi: 10.22625/2072-6732-2022-14-5-51-59.
6. HIV drug resistance report 2021. World Health Organization. Available from: https://www.who.int/publications/i/item/9789240038608. [Accessed: 15th February 2024].
7. Keele, B.F. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1 / B.F. Keele, F. Van Heuverswyn, Y. Li et al. // Science. – 2006. – Vol. 313, No. 5786. – P. 523–6. doi: 10.1126/science.1126531.
8. Faria, N.R. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations / N.R. Faria, A. Rambaut, M.A. Suchard et al. // Science. – 2014. – Vol. 346, No. 6205. – P. 56-61. doi: 10.1126/science.1256739.
9. Visseaux, B. HIV-2 molecular epidemiology / B. Visseaux, F. Damond, S. Matheron et al. // Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. – 2016. – Vol. 46. – P. 233–240. doi: 10.1016/j.meegid.2016.08.010.
10. Giovanetti, M. Molecular Epidemiology of HIV-1 in African Countries: A Comprehensive Overview / M. Giovanetti, M. Ciccozzi, C. Parolin et al. // Pathogens. – 2020. – Vol. 9, No. 12. – P. 1072. doi: 10.3390/pathogens9121072.
11. Bbosa, N. HIV subtype diversity worldwide / N. Bbosa, P. Kaleebu, D. Ssemwanga // Current Opinion in HIV and AIDS. – 2019. – Vol. 14, No. 3. – P. 153-160. doi: 10.1097/COH.0000000000000534.
12. Zhang, M. The role of recombination in the emergence of a complex and dynamic HIV epidemic / M. Zhang, B. Foley, A.K. Schultz et al. // Retrovirology. – 2010. – Vol. 7. – P. 25. doi: 10.1186/1742-4690-7-25.
13. HIV Circulating Recombinant Forms (CRFs). Available from: https://www.hiv.lanl.gov/components/sequence/HIV/crfdb/crfs.comp. [Accessed: 5th November 2024].
14. Shchemelev, A.N. Genetic diversity and drug resistance mutations of HIV-1 in Leningrad Region / A.N. Shchemelev, A.V. Semenov, Y.V. Ostankova et al. // Journal of microbiology, epidemiology and immunobiology. – 2022. – Vol. 99, No. 1. – P. 28-37. doi: 10.36233/0372-9311-216.
15. Schlüsser, M. HIV-1 sub-subtype A6: settings for normalised identification and molecular epidemiology in the Southern Federal District, Russia / M. Schlüsser, V.V. Kartashev, V.H. Mikkola et al. // Viruses. – 2020. – Vol. 12, No. 4. – P. 475. doi: 10.3390/v12040475.
16. Sarafianos, S.G. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs / S.G. Sarafianos, S.H. Hughes, E. Arnold // The international journal of biochemistry & cell biology. – 2004. – Vol. 36, No. 9. – P. 1706-15. doi: 10.1016/j.biocel.2004.02.027.
17. Nastri, B.M. HIV and Drug-Resistant Subtypes / B.M. Nastri, P. Pagliano, C. Zannella et al. // Microorganisms. – 2023. – Vol. 11, No. 1. – P. 221. doi: 10.3390/microorganisms11010221.
18. Clinical recommendations. HIV infection in adults. National Association of HIV Prevention, Diagnosis and Treatment Specialists. Available from: http://rushiv.ru/klinicheskie-rekomendatsii-vich-infektsiya-u-vzroslyh-2020/. [Accessed: 7th March 2024].
19. Ghosh, A.K. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS / A.K. Ghosh, H.L. Osswald, G. Prato // Journal of medicinal chemistry. – 2016. – Vol. 59, No. 11. – P. 5172-208. doi: 10.1021/acs.jmedchem.5b01697.
20. Shtrek, S. Prevalence and Spectrum of HIV-1 Resistance Mutations in the Siberian Federal District / S. Shtrek, L. Levakhina, A. Blokh et al. // Viruses. – 2022. – Vol. 14, No. 10. – P. 2117. doi: 10.3390/v14102117.
21. Dong, K. Prevalence of HIV-1 Drug Resistance among Patients with Antiretroviral Therapy Failure in Sichuan, China, 2010-2016 / K. Dong, L. Ye, Y. Leng et al. // Tohoku J. Exp. Med. – 2019. – Vol. 247, No. 1. – P. 1-12. doi: 10.1620/tjem.247.1.
22. Wagner, T. Epidemiology and Transmitted HIV-1 Drug Resistance among Treatment-Naïve Individuals in Israel, 2010-2018 / T.Wagner, N.S. Zuckerman, T. Halperin et al. // Viruses. – 2021. – Vol. 14, No. 1. – P. 71. doi: 10.3390/v14010071.
23. Wensing, A.M. 2022 update of the drug resistance mutations in HIV-1 / A.M. Wensing, V. Calvez, F. Ceccherini-Silberstein et al. // Topics in antiviral medicine. – 2022. – Vol. 30, No. 4. – P. 559-574.
24. Mirdzhamalova, F.O. The case of multi-drug resistant HIV-1 in children of Novosibirsk region / F.O. Mirdzhamalova, Yu.V. Meshcheryakova, Ye.V. Kazaeva et al. // The Siberian Scientific Medical Journal. – 2012. – Vol. 32, No. 6. – P. 46-54.
25. Mamatkulov, A. Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan / A. Mamatkulov, E. Kazakova, N. Ibadullaeva et al. // AIDS research and human retroviruses. – 2021. – Vol. 37, No. 1. – P. 38-43. doi: 10.1089/AID.2020.0096.
26. Li, R. Prevalence of transmitted drug resistance among ART-naüve HIV-infected individuals, Beijing, 2015-2018 / R. Li, C. Song, D. Chen et al. // J. Glob. Antimicrob. Resist. – 2022. – Vol. 28. – P. 241-248. doi: 10.1016/j.jgar.2022.01.017.
27. Machnowska, P. German HIV-1 Seroconverter Study Group. Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort / P. Machnowska, K. Meixenberger, D. Schmidt et al. // PLoS One. – 2019. – Vol. 14, No. 1. – P. e0209605. doi: 10.1371/journal.pone.0209605.
28. Ozhmegova, E.N. HIV drug resistance: past and current trends / E.N. Ozhmegova, M.R. Bobkova // Problems of Virology (Voprosy Virusologii). – 2022. – Vol. 67, No. 3. – P. 193–205. doi: 10.36233/0507-4088-113.
29. Perelson, A.S. Modeling the within-host dynamics of HIV infection / A.S. Perelson, R.M. Ribeiro // BMC biology. – 2013. – Vol. 11. – P. 96. doi: 10.1186/1741-7007-11-96.
30. Lebedeva, N.N. HIV drug resistance early warning indicators and their assessment in some regions of Russia / N.N. Lebedeva, S.Ya. Zverev, V.V. Kulagin et al. // HIV Infection and Immunosuppressive Disorders. – 2018. – Vol. 10, No. 4. – P. 67–75. doi: 10.22328/2077-9828-2018-10-4-67-75.
31. Sambyalova, A.Yu. Drug monitoring of antiretroviral drugs in children with perinatal HIV infection / A.Yu. Sambyalova, T.A. Bairova, A.V. Belskikh et al. // Acta Biomedica Scientifica. – 2024. – Vol. 9, No. 3. – P. 102– 110. doi: 10.29413/ABS.2024-9.3.10.
32. Mutwa, P.R. Long-term effectiveness of combination antiretroviral therapy and prevalence of HIV drug resistance in HIV-1-infected children and adolescents in Rwanda / P.R. Mutwa, K.R. Boer, J. Rusine et al. // The Pediatric infectious disease journal. – 2014. – Vol. 33, No. 1. – P. 63-9. doi: 10.1097/INF.0b013e31829e6b9f.
33. Fokam, J. Archiving of mutations in HIV-1 cellular reservoirs among vertically infected adolescents is contingent with clinical stages and plasma viral load: Evidence from the EDCTPREADY study / J. Fokam, M.L. Mpouel Bala, M.M. Santoro et al. // HIV medicine. – 2022. – Vol. 23, No. 6. – P. 629-638. doi: 10.1111/hiv.13220.
34. Sambyalova, A.Yu. The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection / A.Yu. Sambyalova, T.A. Bairova, T.L. Manaenkova et al. // Acta Biomedica Scientifica. – 2021. – Vol. 6, No. 6-2. – P. 113-124 doi: 10.29413/ABS.2021-6.6-2.12.
35. Sambyalova, A.Yu. Some pharmacogenetic aspects of the ABCB1 gene in lopinavir / ritonavir concentration variability in children with HIV infection: A pilot study / A.Yu. Sambyalova, T.A. Bairova, T.L. Manaenkova et al. // Acta Biomedica Scientifica. – 2022. – Vol. 7, No. 5-1. – P. 53-61. doi: 10.29413/ABS.2022-7.5-1.7.
36. Rashidova, M.A. HIV and pregnancy: realities of XXI century / M.A. Rashidova, L.F. Sholokhov, A.Yu. Marianian et al. // Sibirskij Nauchnyj Medicinskij Zhurnal. – 2022. – Vol. 42, No. 2. – Р. 10-17 doi: 10.18699/SSMJ20220202.
37. Petrova, A. Impact of combined antiretroviral prophylaxis on health outcomes in HIV exposed neonates / A. Petrova, A. Vaniarkina, J. Plotnikova et al. // Archives of Disease in Childhood. – 2019. – Vol. 104, No. S3. – Р. A4. doi: 10.1136/archdischild-2019-epa.9.
38. Shugaeva, S. Health problems in neonates with perinatal HIV exposure / S. Shugaeva, A. Petrova, A. Vaniarkina et al. // Archives of Disease in Childhood. – 2019. – Vol. 104, No. S3. – Р. A143. doi: 10.1136/archdischild-2019-epa.329.
39. Petrova, A.G. Perinatal HIV infection / A.G. Petrova. – 2 ed., rev. and add. – Irkutsk: INCHT, 2020. – 256 p.
40. Petrovа, A.G. Options for the progression of perinatal HIV infection and the manifestation of HIV-associated pathology in children / A.G. Petrovа, S.V. Smirnova, V.T. Kiklevich et al. // Siberian Medical Journal. – 2009. – Vol. 87, No. 4. – P. 98–100.
41. Ingabire, T. Primary HIV drug resistance among newly HIV type-1 diagnosed patients in St. Petersburg / T. Ingabire, A.V. Semenov, E.V. Esaulenko et al. // HIV Infection and Immunosuppressive Disorders. – 2021. – Vol. 13, No. 1. – P. 70–79 doi: 10.22328/2077-9828-2021-13-1-70-79.
42. Kazennova, Ye.V. Analysis of HIV drugs resistance in Privolzhskiy federal district of the Russian Federation / Ye.V. Kazennova, I.A. Lapovok, A.V. Lebedev et al. // HIV Infection and Immunosuppressive Disorders. – 2015. – Vol. 7, No. 3. – P. 56–66 doi: 10.22328/2077-9828-2015-7-3-56-66.
43. Ponomareva, O.A. Genetic diversity of HIV-1 on the territory of Irkutsk region / O.A. Ponomareva, A.O. Revizor, E.A. Kruglova et al. // Laboratory Service. – 2016. – Vol. 5, No. 1. – P. 33–37.
44. Eliseeva, V.S. Prevalence of HIV-1 drug resistance mutations in Primorsky region / V.S. Eliseeva, S.P. Kruglyak, L.F. Sklyar et al. // HIV Infection and Immunosuppressive Disorders. – 2015. – Vol. 7, No. 2. – P. 49-54. doi: 10.22328/2077-9828-2015-7-2-49-55.
45. Áy, É. Prevalence of resistance mutations associated with integrase inhibitors in therapy-naive HIV-positive patients in Hungary / É. Áy, Á. Pocskay, B. Lakatos et al. // Acta Microbiol. Immunol. Hung. – 2021. – Vol. 68, No. 2. – P. 87-91. doi: 10.1556/030.2021.01433.
46. Avila-Rios, S. Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis / S. Avila-Rios, O. Sued, S.Y. Rhee et al. // PLoS One. – 2016. – Vol. 11, No. 6. – P. e0158560. doi: 10.1371/journal.pone.0158560.
47. Lakhikumar Sharma, A. Prevalence of Drug Resistance Associated Mutations Among the Anti Retroviral Therapy Exposed HIV-1 Infected Individuals in Manipur, Northeast India / A. Lakhikumar Sharma, T. Ramsing Singh, K. Ranjana Devi et al. // Current HIV research. – 2016. – Vol. 14, No. 4. – P. 360-70. doi: 10.2174/1570162x14666160401131426.
48. Gray Neils, M.E. A geospatial bibliometric review of the HIV/AIDS epidemic in the Russian Federation / M.E. Gray Neils, H.OI Pfaeffle, A.T. Kulatti et al. // Frontiers in public health. – 2020. – Vol. 8. – P. 75. doi: 10.3389/fpubh.2020.00075.
Review
For citations:
Nemchinova N.V., Bairova T.A., Sambyalova A.Yu., Belyaeva E.V., Ershova O.A. HIV and antiretroviral drug resistance. Journal Infectology. 2025;17(2):32-41. (In Russ.) https://doi.org/10.22625/2072-6732-2025-17-2-32-41
Views:
82
.png)
.png)
Email this article 